Akcea Therapeutics, Inc. (AKCA) financial statements (2020 and earlier)

Company profile

Business Address 22 BOSTON WHARF RD
BOSTON, MA 02210
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:253253260
Cash and cash equivalents1298658
Short-term investments123166202
Other undisclosed cash, cash equivalents, and short-term investments0(0) 
Receivables155
Inventory, net of allowances, customer advances and progress billings9  
Inventory9  
Contract with customer, asset11 
Other current assets6101
Other undisclosed current assets(0)0 
Total current assets:278267267
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment560
Intangible assets, net (including goodwill)85891
Intangible assets, net (excluding goodwill)85891
Other noncurrent assets431
Total noncurrent assets:105982
TOTAL ASSETS:383365269
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities303514
Accounts payable6122
Accrued liabilities15158
Employee-related liabilities994
Deferred revenue11
Due to related parties 1914
Deferred revenue and credits51
Contract with customer, liability25
Other liabilities212
Total current liabilities:438181
Noncurrent Liabilities
Long-term debt and lease obligation15  
Operating lease, liability15
Liabilities, other than long-term debt 88
Deferred revenue and credits8
Contract with customer, liability3
Deferred rent credit 4
Total noncurrent liabilities:1588
Total liabilities:588989
Stockholders' equity
Stockholders' equity attributable to parent325277180
Common stock000
Additional paid in capital889799464
Accumulated other comprehensive loss(0)(0)(0)
Accumulated deficit(564)(522)(284)
Total stockholders' equity:325277180
TOTAL LIABILITIES AND EQUITY:383365269

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Revenues2216555
Cost of revenue
(Cost of Goods and Services Sold)
(2)(3) 
Gross profit:2196255
Operating expenses(357)(296)(164)
Other undisclosed operating income213 
Operating loss:(117)(231)(109)
Nonoperating income652
Investment income, nonoperating662
Interest and debt expense  (2)
Loss from continuing operations before income taxes:(112)(225)(108)
Income tax expense(1)(0)(1)
Net loss attributable to parent:(112)(226)(110)
Preferred stock dividends and other adjustments  (20)
Other undisclosed net loss available to common stockholders, basic(13)(8) 
Net loss available to common stockholders, diluted:(126)(234)(130)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss:(112)(226)(110)
Comprehensive loss:(112)(226)(110)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)
Comprehensive loss, net of tax, attributable to parent:(112)(226)(110)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: